Moderna, Inc. (NASDAQ:MRNA) Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 55.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,790 shares of the company's stock after selling 20,037 shares during the quarter. QRG Capital Management Inc.'s holdings in Moderna were worth $1,055,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company's stock worth $4,159,769,000 after acquiring an additional 5,129,800 shares during the period. International Assets Investment Management LLC grew its stake in Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company's stock valued at $21,353,000 after acquiring an additional 316,552 shares during the period. Intech Investment Management LLC increased its stake in shares of Moderna by 1,212.9% during the first quarter. Intech Investment Management LLC now owns 330,805 shares of the company's stock worth $35,251,000 after purchasing an additional 305,609 shares in the last quarter. Matrix Capital Management Company LP boosted its stake in Moderna by 60.8% during the 1st quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company's stock worth $77,789,000 after purchasing an additional 276,000 shares during the last quarter. Finally, Motley Fool Wealth Management LLC purchased a new stake in shares of Moderna during the first quarter worth $21,317,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MRNA shares. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Sanford C. Bernstein assumed coverage on shares of Moderna in a research report on Thursday, October 17th. They set a "market perform" rating and a $55.00 price target for the company. Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a report on Friday. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a report on Friday. Finally, HSBC raised Moderna from a "reduce" rating to a "hold" rating and set a $82.00 target price on the stock in a research report on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $93.18.

Moderna Stock Down 6.9 %

MRNA stock traded down $3.45 during midday trading on Friday, reaching $46.83. 13,561,538 shares of the company were exchanged, compared to its average volume of 4,882,079. The company has a market cap of $18.00 billion, a price-to-earnings ratio of -3.04 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna, Inc. has a 1-year low of $46.57 and a 1-year high of $170.47. The stock's 50-day simple moving average is $61.85 and its 200 day simple moving average is $99.22.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.39) earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -9.89 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Moderna news, CFO James M. Mock sold 715 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock worth $238,531 in the last quarter. 15.70% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.